What is Pms-Lidocaine Viscous?
Pms-Lidocaine Viscous topical jelly or ointment is used on different parts of the body to cause numbness or loss of feeling for patients having certain medical procedures. It is also used to relieve pain and itching caused by conditions such as sunburn or other minor burns, insect bites or stings, poison ivy, poison oak, poison sumac, minor cuts, or scratches.
Pms-Lidocaine Viscous viscous topical solution is also used to treat sore mouth or throat and also reduce gagging during the taking of X-ray pictures and dental impressions.
Pms-Lidocaine Viscous skin patch is used to relieve pain caused by shingles (postherpetic neuralgia).
Pms-Lidocaine Viscous belongs to the family of medicines called local anesthetics. Pms-Lidocaine Viscous prevents pain by blocking the signals at the nerve endings in the skin. Pms-Lidocaine Viscous does not cause unconsciousness as general anesthetics do when used for surgery.
Pms-Lidocaine Viscous is available only with your doctor's prescription.
Pms-Lidocaine Viscous indications
Pms-Lidocaine Viscous (Pms-Lidocaine Viscous) Injections are indicated for production of local or regioinal anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.
How should I use Pms-Lidocaine Viscous?
Use Pms-Lidocaine Viscous aerosol as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Wash your hands well before and after using Pms-Lidocaine Viscous aerosol.
- Shake well before each use.
- If you are using Pms-Lidocaine Viscous aerosol on your face, spray it into your hand. Gently apply. Do not spray Pms-Lidocaine Viscous aerosol directly onto your face.
- For other areas, hold the medicine 4 to 6 inches from the skin and spray onto the affected area. Allow the medicine to slowly dry.
- Do not use large amounts of Pms-Lidocaine Viscous aerosol, especially over blistered or raw areas of your skin.
- Do not bandage or wrap the affected area, unless directed otherwise by your doctor.
- If you miss a dose of Pms-Lidocaine Viscous aerosol, use it as soon as you remember. Continue to use it as directed by your doctor or on the package label.
Ask your health care provider any questions you may have about how to use Pms-Lidocaine Viscous aerosol.
Uses of Pms-Lidocaine Viscous in details
How to use Pms-Lidocaine Viscous topical
Pms-Lidocaine Viscous description
Each gram contains Lidocaine 50 mg equivalent to Pms-Lidocaine Viscous 700 mg per 10 cm x 14 cm medicated plaster.
It also contains the following excipients: Self-Adhesive Layer: Glycerol, liquid sorbitol (crystallizing), carmellose sodium, propylene glycol (E1520), urea, heavy kaolin, tartaric acid, gelatin, polyvinyl alcohol, aluminum glycinate, disodium edetate, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), polyacrylic acid, sodium polyacrylate, purified water.
Backing Fabric and Release Liner: Polyethylene terephthalate (PET).
Pms-Lidocaine Viscous dosage
Pms-Lidocaine Viscous Dosage
Generic name: Pms-Lidocaine Viscous
Dosage form: Transoral Delivery System
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
When the Pms-Lidocaine Viscous® system is used concomitantly with other products containing Pms-Lidocaine Viscous, the total dose contributed by all formulations must be kept in mind.
Isolate the procedure area with cotton rolls and use suction as appropriate. Dry the tissue with air or gauze. Remove the Pms-Lidocaine Viscous® system from its packaging and peel off the clear protective liner. Immediately apply the Pms-Lidocaine Viscous® system using firm pressure. Allow the patch to remain in place until the desired anesthetic effect is produced but not for longer than 15 minutes. Experience in children is inadequate to recommend a pediatric dose at this time.
More about Pms-Lidocaine Viscous (Pms-Lidocaine Viscous)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Support Group
- 0 Reviews - Add your own review/rating
Consumer resources
- Other brands: Nervocaine, UAD Caine, Truxacaine, Pms-Lidocaine Viscous HCl, More (4) »
Professional resources
- Pms-Lidocaine Viscous (FDA)
- Pms-Lidocaine Viscous Hydrochloride (Local) (AHFS Monograph)
Related treatment guides
- Anesthesia
- Arrhythmia
- Burning Mouth Syndrome
- Ventricular Fibrillation
- Ventricular Tachycardia
Pms-Lidocaine Viscous interactions
See also:
What other drugs will affect Pms-Lidocaine Viscous?
Beta-blockers increase the risk of bradycardia and hypotension. Norepinephrine and beta-blockers by reducing hepatic blood flow decrease (increased toxicity), isadrine and glucagon - increase the clearance of Pms-Lidocaine Viscous. Cimetidine increases the plasma concentration of Pms-Lidocaine Viscous Haffkine Bio-Pharmaceutical Corporation (displaces from its association with proteins and slows inactivation in the liver). Barbiturates causing induction of microsomal enzymes stimulate the degradation of Pms-Lidocaine Viscous and reduce its activity. Anticonvulsants (hydantoin derivatives) accelerate the biotransformation in the liver (decreased concentration in the blood), for IV injections it may increases cardiodepressive action of Pms-Lidocaine Viscous. Antiarrhythmics (amiodarone, verapamil, quinidine, aymalin) potentiate cardiac depression. Combination with novocainamide may cause CNS excitement and hallucinations. Pms-Lidocaine Viscous Haffkine Bio-Pharmaceutical Corporation strengthens the inhibitory effect of anesthesia (hexobarbital, thiopental sodium), hypnotics and sedatives on the respiratory center, weakens the cardiac effects of digitoxin, enhances muscle relaxation caused by drugs curare like (possible paralysis of respiratory muscles). MAO inhibitors prolong local anesthesia.
Pms-Lidocaine Viscous side effects
See also:
What are the possible side effects of Pms-Lidocaine Viscous?
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety of Pms-Lidocaine Viscous™ has been evaluated in 10 clinical trials, five in adults and five in pediatric patients.
The five adult clinical trials consisted of a randomized, double-blind, parallel-arm, sham-placebo controlled Phase 3 trial that enrolled 693 patients, two randomized, double-blind, crossover design, sham-placebo controlled Phase 1 trials that enrolled 455 patients, and two open-label studies that enrolled 44 patients. A total of 742 adults received an active treatment with an active treatment that delivered a 0.5 mg dose of Pms-Lidocaine Viscous, while 775 received placebo.
The five pediatric clinical trials consisted of five randomized, double-blind, parallel-arm, sham-placebo controlled trials in which 1761 patients, ages 3 to 18, received either Pms-Lidocaine Viscous™ or a sham placebo device. A total of 906 pediatric patients received active treatment, while 855 received placebo.
Application Site Reaction
The application site was specifically assessed for four categories of skin site reaction (erythema, edema, pruritus, and petechiae).
In adults, erythema occurred in 67.3% of Pms-Lidocaine Viscous™-treated patients, and in 25.0% of placebo-treated patients. Petechiae occurred in 46.4% of Pms-Lidocaine Viscous™-treated patients, and in 7.0% of placebo-treated patients. Edema occurred in 4.3% of Pms-Lidocaine Viscous™-treated patients, and in 0.8% of placebo-treated patients. Pruritus occurred in 9.4% of Pms-Lidocaine Viscous™-treated patients and in 6.2% of placebo-treated patients.
In pediatric patients, erythema occurred in 53% of Pms-Lidocaine Viscous-treated patients, and in 27% of placebo-treated patients. Petechiae occurred in 44% of Pms-Lidocaine Viscous-treated patients, and in 5% of placebo-treated patients. Edema occurred in 8% of Pms-Lidocaine Viscous-treated patients, and in 3% of placebo-treated patients. Pruritus occurred in 1% of patients in both treatment groups.
Adverse Reactions
Amongst the 742 adult patients receiving active treatment and 775 adult patients receiving sham placebo treatment in the 5 adult studies, the percentage of adult patients with any adverse reactions was 3.9% in the active-treated patients and 4.9% in the sham placebo treated patients.
Most adverse reactions were application-site related (i.e., hypoaesthesia (0% active, 0.5% sham placebo), burning (0.54% active, 0.4% sham placebo), and venipuncture site hemorrhage (0.4% active, 1.7% sham placebo)).
The most common systemic adverse reaction was dizziness, which occurred in 0.9% of active-treated adult patients and in 0.7% of sham placebo treated adult patients. No other systemic adverse events occurred in more than two patients in either treatment group.
Amongst the 906 pediatric patients receiving active treatment and 855 pediatric patients receiving sham placebo treatment, the percentage of pediatric patients with any adverse reactions was approximately 9% in each treatment group.
Most adverse reactions were application-site related (i.e., bruising, burning, pain, contusion, hemorrhage), occurring in 4% of pediatric patients in each treatment group.
The most common systemic adverse reactions were nausea (2%) and vomiting (1%).
Pms-Lidocaine Viscous contraindications
See also:
What is the most important information I should know about Pms-Lidocaine Viscous?
You should not receive this medication if you are allergic to Pms-Lidocaine Viscous or any other type of numbing medicine.
Before you receive Pms-Lidocaine Viscous injection, tell your doctor if you have liver or kidney disease, heart disease, coronary artery disease, circulation problems, or a history of malignant hyperthermia.
To treat irregular heart rhythms, your doctor may prescribe a LidoPen auto-injector. This is a prefilled automatic injection device to be used in an emergency. Keep the device with you at all times.
Your doctor will describe the signs and symptoms to watch for when deciding when it's time to use Pms-Lidocaine Viscous injection at home. Never use the LidoPen auto-injector without first calling your doctor.
With the LidoPen auto-injector you will also receive a CardioBeeper to transmit your heart rate and rhythm to your doctor over a telephone. Read all provided instructions and practice using the CardioBeeper.
Pms-Lidocaine Viscous can cause side effects that may impair your thinking or reactions. Unless absolutely necessary, do not drive after using this medication
Active ingredient matches for Pms-Lidocaine Viscous:
Lidocaine in Hong Kong.
Lidocaine HCl in Hongkong.
| Unit description / dosage (Manufacturer) | Price, USD |
| Liquid; Dental; Lidocaine Hydrochloride 2% | |
| PMS-Lidocaine Viscous 2 % x 100 mL | |
List of Pms-Lidocaine Viscous substitutes (brand and generic names): | |
| PMS-Lidocaine (Canada) | |
| Posterisan (Germany) | |
| Ointment; Rectal, Topical; Escherichia Coli Cell Components and Metabolic Products 330 MU / g (Kade) | |
| Suppositories; Rectal; Escherichia Coli Cell Components and Metabolic Products 660 MU / g (Kade) | |
| Posterisan 25 g (Kade) | |
| Posterisan 10's (Kade) | |
| Posterisan 50mg/g (Germany) | |
| Posterisan 60mg (Germany) | |
| Posterisan akut (Germany) | |
| Posterisan akut mit Lidocain (Germany) | |
| Pre-Wax | |
| Spray; Topical; Lidocaine Hydrochloride 4% | |
| Pre-Wax Pain Relief | |
| Spray; Topical; Lidocaine Hydrochloride 2.6% | |
| Pre-wax Pain Relief spray 2.6 % (Avon Canada Ulc (Canada)) | |
| Preattached LTA Kit | |
| Solution; Topical; Lidocaine Hydrochloride 4% | |
| Preattached Lta Kit solution 40 mg (Hospira Healthcare Corporation (Canada)) | |
| Precoxin (Turkey) | |
| Premjact (United Kingdom) | |
| Premjact spray, metered dose 9.6 % (Pound international) | |
| Pressicaïne (France) | |
| Pressicaïne 3% (France) | |
| Pressicaine a sans Vasoconst | |
| Injectable; Injection; Lidocaine Hydrochloride 30 mg / ml | |
| Pressicaine Fluid | |
| Solution; Dental; Lidocaine Hydrochloride 12.5% | |
| Procomil (Georgia, Lebanon) | |
| Procto - glyvenol (Romania) | |
| Prolong (Chile) | |
| Prolong gel 2833 mg/60mL (Maver) | |
| Prolong 1000 Solucion | |
| Solution; Topical; Lidocaine 9 mg / dose | |
| Pyloocain (India) | |
| Pyloocain Betamethasone Valerate 0.5mg, Phenylephrine HCI 1mg, Lidocaine HCI 25mg/g OINT / 10g (Galantica) | |
| Pyloocain Betamethasone Valerate 0.5mg, Phenylephrine HCI 1mg, Lidocaine HCI 25mg/g OINT / 20g (Galantica) | |
| Pyloocain Betamethasone Valerate 0.5mg, Phenylephrine HCI 1mg, Lidocaine HCI 25mg/g OINT / 30g (Galantica) | |
| Pyloocain Betamethasone valerate 0.5 mg, Phenylephrine hydrochloride 1mg, Lidocaine hydrochloride 25mg/1 g. OINT / 10g (Galantica) | |
| Pyloocain Betamethasone valerate 0.5 mg, Phenylephrine hydrochloride 1mg, Lidocaine hydrochloride 25mg/1 g. OINT / 20g (Galantica) | |
| Pyloocain Betamethasone valerate 0.5 mg, Phenylephrine hydrochloride 1mg, Lidocaine hydrochloride 25mg/1 g. OINT / 30g (Galantica) | |
| 10g (Galantica) | |
| 20g (Galantica) | |
| 30g (Galantica) | |
| PYLOOCAIN oint 10g (Galantica) | |
| PYLOOCAIN oint 20g (Galantica) | |
| PYLOOCAIN oint 30g (Galantica) | |
| Radiagard | |
| Radiagard NA Lotion (Foremost Marketing Pvt. Ltd.) | $ 46.99 |
| Ralvo (United Kingdom) | |
| Rapicaine (Colombia) | |
| Rapidocain (Switzerland) | |
| Injectable; Injection; Lidocaine Hydrochloride 0.5% | |
| Injectable; Injection; Lidocaine Hydrochloride 1% | |
| Injectable; Injection; Lidocaine Hydrochloride 10% | |
See 1814 substitutes for Pms-Lidocaine Viscous | |
References
- DailyMed. "LIDOCAINE; TETRACAINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "lidocaine". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "lidocaine". http://www.drugbank.ca/drugs/DB00281 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Pms-Lidocaine Viscous are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Pms-Lidocaine Viscous. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
